VDV Pharma
ActiveThe computed 12-month bankruptcy probability of VDV Pharma is 2.8% (moderate). The 2025 annual accounts show equity of €201k and a net result of €66k. Equity is growing by ~47.9% per year across the filed fiscal years. Its solvency ranks better than 24% of 4149 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
48
/ 100
Fair
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability74▼-3
Solvency38▲+5
Growth78=
Track record100
Bankruptcy probability, 12 months
2.8%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €9k at 30 days acceptable
Liquidity short (current ratio 0.47 against 0.49 in 2024; short-term debt: 48.6% and cash: 4.1% of total assets), and 86.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
13.3%
Return on assets
4.4%
Age of the figures
15 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 24% of 4149 sector peers (2025).
NBB · sector comparisonPosition among 4149 sector peers
Solvency
better than 24%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 17-11-2025, 75 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
75 d early
2024
24 d early
2023
8 d early
2022
50 d early
2021
27 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
30-06-2026 close22-09-2026 today31-01-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€66k▼ 37.7%
2024 · €107k
2021: €17k
2022: €122k
2023: €84k
2024: €107k
2021 → 2025
Working capital
€-392k▲ 11.1%
2024 · €-441k
2021: €36k
2022: €155k
2023: €-325k
2024: €-441k
2021 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€42k-€164k▲ 292%€248k▲ 51.5%€135k▼ 45.6%€201k▲ 49.1%
Operating result€27k-€162k▲ 501%€132k▼ 18.8%€162k▲ 23.0%€109k▼ 32.5%
Net result€17k-€122k▲ 624%€84k▼ 30.8%€107k▲ 26.2%€66k▼ 37.7%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 32% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.52M
Fixed assets
€1.17M▼ 2.6%
Current assets
€345k▼ 18.0%
Equity and liabilities €1.52M
Equity
€201k▲ 49.1%
Debt
€1.32M▼ 11.7%
The debt ratio falls from 91.7% to 86.7%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€183k▼
2024 · €232k
Cash flow
€140k▼
2024 · €176k
Solvency
13.3%▲
2024 · 8.3%
Current ratio
0.47▼
2024 · 0.49
Quick ratio
0.31▼
2024 · 0.36
Debt / equity
6.54▼
2024 · 11.04
ROE
33.0%▼
2024 · 78.9%
ROA
4.4%▼
2024 · 6.6%
Interest coverage
7.43▼
2024 · 8.91
Debt
€1.32M▼
2024 · €1.49M
Debt ≤ 1 year
€737k▼
2024 · €862k
Debt > 1 year
€579k▼
2024 · €627k
Income taxes
€19k▼
2024 · €32k
Staff costs
€95k▲
2024 · €65k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€1.63M€1.52M▼
Formation expenses20€210€8▼
Fixed assets21/28€1.20M€1.17M▼
Intangible fixed assets21€353k€304k▼
Tangible fixed assets22/27€343k€361k▲
Land and buildings22€319k€314k▼
Plant, machinery and equipment23€21k€18k▼
Furniture and vehicles24€3k€3k▼
Leasing and similar rights25-€26k
Financial fixed assets28€508k€508k=
Current assets29/58€421k€345k▼
Stocks and contracts in progress3€107k€119k▲
Stocks30/36€107k€119k▲
Amounts receivable within one year40/41€126k€91k▼
Trade receivables40€89k€80k▼
Other amounts receivable41€38k€12k▼
Current investments50/53€45k€69k▲
Cash at bank and in hand54/58€140k€63k▼
Deferred charges and accrued income490/1€3k€4k▲
Equity and liabilities
Total equity and liabilities10/49€1.63M€1.52M▼
Equity10/15€135k€201k▲
Contributions10/11€25k€25k=
Profit (loss) carried forward14€110k€176k▲
Amounts payable17/49€1.49M€1.32M▼
Amounts payable after more than one year17€627k€579k▼
Financial debts170/4€627k€579k▼
Amounts payable within one year42/48€862k€737k▼
Current portion of amounts payable after more than one year42€67k€74k▲
Financial debts43€30k€30k=
Credit institutions430/8€30k€30k=
Trade debts44€50k€50k▲
Suppliers440/4€50k€50k▲
Taxes, remuneration and social security45€16k€19k▲
Taxes450/3€4k€327▼
Remuneration and social security454/9€12k€19k▲
Other amounts payable47/48€699k€564k▼
Accrued charges and deferred income492/3€1k€0▼
Income statement
Code20242025
Remuneration, social security and pensions62€65k€95k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€69k€73k▲
Other operating charges640/8€5k€3k▼
Gross operating margin9900€302k€282k▼
Operating profit (loss)9901€162k€109k▼
Financial income75/76B€2k€0▼
Recurring financial income75€2k€0▼
Financial charges65/66B€26k€25k▼
Recurring financial charges65€26k€25k▼
Profit (loss) for the period before taxes9903€138k€85k▼
Income taxes67/77€32k€19k▼
Profit (loss) for the period9904€107k€66k▼
Profit (loss) for the period to be appropriated9905€107k€66k▼
Appropriation of the result
Profit (loss) to be appropriated9906€330k€176k▼
Profit (loss) brought forward from the previous period14P€223k€110k▼
Profit to be distributed694/7€220k€0▼
Return on contributions (dividend)694€220k€0▼
Social balance
Average headcount (FTE)90870.91.5▲
The notes to these accounts (21 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2025
17-11
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
30-06
Financial
Equity above €200kEq €201k ▲49.1%
5 profitable years in a row build equity to €201k.
07-01
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
23-01
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
30-06
Financial
Equity above €200kEq €248k ▲51.5%
3 profitable years in a row build equity to €248k.
2022
12-12
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
30-06
Financial
Highest result since 2021net €122k ▲624%
Operating result €162k, net result €122k, both a record.
30-06
Financial
Equity above €150kEq €164k ▲292%
2 profitable years in a row build equity to €164k.
04-01
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Schaarbeek · 1 establishment unit since 2020
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Helmetsesteenweg 3731030 SchaarbeekGround area
245 m²
Building footprint
109 m²
Volume, LiDAR
1,510 m³
Parcel 21015A0203/00Z002, Brussels · tallest building 16.6 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
VDV Pharma
since 20202.307.739.569
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21015A0203/00Z002 | Brussels | 245 m² | 1 · 109 m² | 16.6 m · 5 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
APOTHEEK GOETHALS
BE 0866.235.041
Wevelgem · Eq €202k
BVV
BE 0760.315.494
Affligem · Eq €201k
Apotheek Bijnens
BE 0446.676.387
Hasselt · Eq €202k
APOTEEK JACOBS
BE 0454.398.775
Ranst · Eq €201k
PHARMACIE D'AVROY
BE 0439.294.192
Liège · Eq €201k
Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 3,562 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded16-07-2020
Fiscal year end30-06
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 5 filingsAddress and cadastre registers
Data from official sources, last processed on 22-09-2026. Scores and ratios are computed by Checked and are not a credit decision.